Howard Sofen, M.D.

Insurance Accepted

• Aetna Choice POS II
• Cigna
• First Health PPO
• Great West PPO
• Humana
• Multiplan PPO
• United Healthcare

Languages Spoken

• English

Education & Training

Medical Degree

Drexel University College of Medicine

Internship(s)

University of Southern California - LAC+USC Medical Center

Residency(ies)

UCLA VA Wadsworth

US Department Of Veterans Affairs

Fellowship(s)

Publications & Media

• Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.

  Sofen, H., Hudson, C. P., Cook-Bolden, F. E., Preston, N., Colon, L. E., Caveney, S. W., Gottschalk, R. W.

• Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

  Kalb, R. E., Blauvelt, A., Sofen, H. L., Chevrier, M., Amato, D., Calabro, S., Wang, J., Schenkel, B., Gottlieb, A. B.

• A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.

  Sofen, H., Gross, K. G., Goldberg, L. H., Sharata, H. H., Hamilton, T. K., Egbert, B. M., Lyons, B., Hou, J., Caro, I.

• Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

  Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.

• An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.

  Hudson, C. P., Kempers, S., Menter, A., Papp, K., Smith, S., Sofen, H., Colón, L. E., Johnson, L. A., Gottschalk, R.

• Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.

  Kimball, A. B., Papp, K. A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H., Yeilding, N., Li, S., Szapary, P., Gordon, K. B.

• Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.

  Griffiths, C. E., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S. T., Bachinsky, M., Mallbris, L., Mamolo, C.

• Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.

  Guenther, L., Han, C., Szapary, P., Schenkel, B., Poulin, Y., Bourcier, M., Ortonne, J. P., Sofen, H. L.

• Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.

  Del Rosso, J. Q., Sofen, H., Leshin, B., Meng, T., Kulp, J., Levy, S.

• The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

  Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D. J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A. B., Guttman-Yassky, E.

• Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis.

  Gooderham, M., Elewski, B. E., Pariser, D. M., Sofen, H., Mendelsohn, A. M., Rozzo, S. J., Li, Q.

• Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US.

  Goldstein, S., Eftekhari, S., Mitchell, L., Winders, T. A., Kaufman, L., Dudas, D., Paknis, B., Kavati, A., Delwart, V., Sofen, H. L.

• Treatment of generalised pustular psoriasis with isotretinoin.

  Sofen, H. L., Moy, R. L., Lowe, N. J.